Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 643 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Disease Clear all
Completed Phase 2 Interventional Results available

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

NCT04734210
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate, Placebo
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Not applicable Interventional Results available

TearCare System to Treat Dry Eye Disease

NCT03857919
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare, LipiFlow
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Scottsdale, Arizona • Laguna Hills, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 1 Interventional

Topical Naloxone to Diagnose Ocular Pain

NCT04454281
View directory record Official record
Conditions
Dry Eye Syndromes, Neuropathic Pain
Interventions
Naloxone Hydrochloride 0.4 MG/ML
Drug
Lead sponsor
Seema Capoor
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 16, 2026, 8:41 AM EDT
Terminated Not applicable Interventional Results available

Management of Signs and Symptoms Associated With Dry Eye Disease

NCT04015219
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Self retained cryopreserved amniotic membrane, lifitegrast ophthalmic solution
Device · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

NCT03414645
View directory record Official record
Conditions
Dry Eye, Graft-versus-host-disease, Ocular Discomfort
Interventions
CAM-101 10%, Vehicle Control, CAM-101 30%
Biological
Lead sponsor
Cambium Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 16, 2026, 8:41 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03636061
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004

NCT04523142
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
CyclASol Ophthalmic Solution
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Carmel, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 16, 2026, 8:41 AM EDT
Recruiting Phase 2 Interventional

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

NCT07503886
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
DFL24498, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Chandler, Arizona • Azusa, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

NCT01319773
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine ophthalmic emulsion Formulation A, cyclosporine ophthalmic emulsion Formulation B, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK

NCT00411827
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
PRK with conjunctival impression cytology before and after surgery, LASIK with conjunctival impression cytology before and after surgery
Procedure
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
21 Years to 40 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 1 Interventional

Cyclosporine Implant for Ocular Graft-Versus-Host Disease

NCT00102583
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Subconjunctival Cyclosporine Implant
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
9 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 8:41 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Fullerton, California • La Palma, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

Preventive Approach to Congenital Heart Block With Hydroxychloroquine

NCT01379573
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
Interventions
Hydroxychloroquine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

NCT04391894
View directory record Official record
Conditions
Dry Eye
Interventions
ECF843, ECF843 vehicle
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Evaluation of the Clinical Utility and Safety of the Visant Medical Canalicular Plug

NCT04817085
View directory record Official record
Conditions
Dry Eye
Interventions
Visant Medical Canalicular Plug, Commercially available canalicular plug
Device
Lead sponsor
Visant Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Newport Beach, California • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 16, 2026, 8:41 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

NCT06544642
View directory record Official record
Conditions
Healthy Volunteers, Sjögren's Syndrome
Interventions
ASP5502, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 16, 2026, 8:41 AM EDT
Not listed Not applicable Interventional

Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

NCT03691636
View directory record Official record
Conditions
Dry Eye
Interventions
Eyelash prostheses, 5.0% Lifitegrast Ophthalmic Solution
Device
Lead sponsor
D.E.L., LLC
Industry
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Washington, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

NCT03527212
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
SJP-0035 0.001%, Placebo
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Chandler, Arizona • Sun City, Arizona • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 16, 2026, 8:41 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Tears Substitutions and Their Effects on Higher Order Aberrometery

NCT00812721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Preservative Free Saline, Optive, Refresh Moderate/Severe, Systane, Systane Ultra
Other
Lead sponsor
Gina Rogers
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 16, 2026, 8:41 AM EDT
Recruiting Phase 3 Interventional

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

NCT06747949
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
Dazodalibep
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
31
States / cities
Avondale, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Early Phase 1 Interventional

Preventive IVIG Therapy for Congenital Heart Block

NCT00460928
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block
Interventions
intravenous immune globulin (IVIG)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Livingston, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The THINK Study Incidence of Neurotrophic Keratopathy)

NCT06482164
View directory record Official record
Conditions
Dry Eye
Interventions
Dry Eye Disease
Diagnostic Test
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Laguna Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 16, 2026, 8:41 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)

NCT04535947
View directory record Official record
Conditions
Dry Eye
Interventions
Vehicle, SDP-4 Ophthalmic Solution (1.0%)
Drug
Lead sponsor
Silk Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Garden Grove, California • Murrieta, California • Newport Beach, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 16, 2026, 8:41 AM EDT